Product ID:RIFAMPICIN, 557303
MSDS Date:06/07/1999
FSC:6505
NIIN:00N092493
Status Code:A
MSDS Number: CJSPJ

Emergency Phone: (800)424-9300

Info Phone: 800-854-3417

Cage: 29089

Telephone: 619-450-5558; 800-854-3417

Cage: 29089

(ORAL, RAT) 1570 MG/KG

CAS: 13292-46-1

RTECS: VJ7000000

LD50 LC50 Mixture:SEE INGREDIENT AND TOXICOLOGICAL INFO
Routes of Entry: Inhalation:YES Skin:YES Ingestion:YES
Reports of Carcinogenicity:NTP:NO IARC:NO OSHA:NO
Health Hazards Acute and Chronic:ACUTE EFFECTS: MAY BE HARMFUL BY
INGESTION, INHALATION OR ABSORPTION THROUGH SKIN. MATERIAL MAY
CAUSE IRRITATION TO THE EYES, SKIN, MUCOUS MEMBRANES, AND THE UPPER
RESPIRATORY TRACT. EXPOSURE TO MATER IAL MAY CAUSE THE FOLLOWING:
NAUSEA, VOMITING, ABDOMINAL CRAMPS, DIARRHEA, HEADACHE, FATIGUE,
DROWSINESS, DIZZINESS, FAILURE OF MUSCLE COORDINATION, CONFUSION,
GENERALIZED NUMBNESS, PAIN IN THE EXTREM ITIES, MUSCLE WEAKNESS,
DECREASE IN THE NUMBER OF BLOOD PLATELETS, REDUCTION IN THE NUMBER
OF LEUKOCYTES IN THE BLOOD, ANEMIA, FEVER, SKIN RASH, RENAL
INSUFFICIENCY, ACUTE RENAL FAILURE AND JAUNDICE. (EFFECTS OF
OVEREXPOSURE)
Effects of Overexposure:HEALTH HAZARDS: CHRONIC EFFECTS: THERE IS
LIMITED EVIDENCE THAT RIFAMPICIN IS TERATOGENIC AND TUMORIGENIC IN
LABORATORY ANIMALS. THERE IS ALSO LIMITED EVIDENCE THAT RIFAMPICIN
IS MUTAGENIC IN LABORATO RY CELL CULTURES. UNTIL FURTHER TESTING
HAS BEEN DONE, IT SHOULD BE TREATED AS A POSSIBLE TERATOGEN,
MUTAGEN AND TUMORIGEN IN HUMANS.

First Aid:SKIN: IN CASES OF SKIN CONTACT, WASH IMMED W/COPIOUS AMOUNTS
OF WATER FOR AT LEAST 15 MINUTES. REMOVE CONTAMINATED CLOTHING AND
SHOES AND WASH BEFORE WEARING. CONSULT MD. EYES: IN CASES OF EYE
CONTACT , FLUSH IMMED W/COPIOUS AMOUNTS OF WATER FOR AT LEAST 15
MINUTES. ASSURE ADEQUATE FLUSHING BY SEPARATING EYELIDS W/FINGERS.
CONSULT MD. INHAL: IN CASES OF INHALATION, REMOVE TO FRESH AIR AND
MONITOR B REATHING. IF BREATHING BECOMES DIFFICULT, GIVE OXYGEN AND
CONSULT MD. IF BREATHING STOPS, GIVE ARTIFICIAL RESPIRATION AND
CONSULT MD. INGEST: IN CASES OF INGESTION, WASH MOUTH OUT W/WATER
AND CONSULT LOCAL POISON CENTER AND MD.

Extinguishing Media:DRY CHEMICAL POWDER, CARBON DIOXIDE, WATER SPRAY,
ALCOHOL OR POLYMER FOAM.
Fire Fighting Procedures:USE NIOSH APPROVED SCBA AND FULL PROTECTIVE
EQUIPMENT TO PREVENT CONTACT WITH SKIN AND EYES.
Unusual Fire/Explosion Hazard:UPON THERMAL DECOMPOSITION, IT MAY EMIT
TOXIC GASES.

Spill Release Procedures:EVACUATE AREA. WEAR A NIOSH APPROVED
RESPIRATOR, CHEMICAL SAFETY GOGGLES, RUBBER BOOTS AND HEAVY RUBBER
GLOVES. SWEEP UP AND PLACE IN A SUITABLE CONTAINER. AVOID RAISING
DUST. HOLD FOR APPROPRIATE DIS POSAL. WASH SPILL SITE AND VENTILATE
AREA AFTER MATERIAL PICKUP IS COMPLETE.

Handling and Storage Precautions:STORE IN A TIGHTLY CLOSED CONTAINER IN
A COOL, DRY PLACE (+20C). MATERIAL IS HARMFUL AND AN IRRITANT.
POSSIBLE TERATOGEN, MUTAGEN AND TUMORIGEN. AVOID CONTACT WITH
MATERIAL. AVOID PROLONGED OR REPEATE D EXPOSURE.
Other Precautions:LAB SHOULD BE EQUIPPED WITH A SAFETY SHOWER AND AN
EYE WASH STATION. WASH THOROUGHLY AFTER HANDLING MATERIAL.

Respiratory Protection:USE A NIOSH APPROVED RESPIRATOR.
Ventilation:HANDLE IN A CHEMICAL FUME HOOD.
Protective Gloves:CHEMICAL RESISTANT GLOVES.
Eye Protection:ANSI APPROVED CHEMICAL WORKERS GOGGLES .
Other Protective Equipment:ANSI APPROVED EYE WASH AND DELUGE SHOWER .
WEAR SUITABLE PROTECTIVE CLOTHING.
Supplemental Safety and Health
PHYSICAL DATA: SOLUBILITY: SOLUBLE IN DMSO. RIFAMPICIN: MOLECULAR
WEIGHT: 823.0; MOLECULAR FORMULA: C*43H*58N*4O*12.

Melt/Freeze Pt:>183.C, 361.4F
Appearance and Odor:RED SOLID.

Stability Indicator/Materials to Avoid:YES
N/A.
Stability Condition to Avoid:N/A. STABLE UNDER NORMAL HANDLING
PROCEDURES.
Hazardous Decomposition Products:UPON THERMAL DECOMPOSITION, MAY EMIT
TOXIC GASES INCLUDING CARBON MONOXIDE, CARBON DIOXIDE AND NITROGEN
OXIDE.

Waste Disposal Methods:COUNTRY, FEDERAL, STATE & LOCAL REGS ARE VAIRED
& CHANGE FREQUENTLY. FOR THIS REASON, WE RECOMMEND THAT YOU CONT
YOUR LOCAL DEPARTMENT OF HEALTH SERVICES FOR INFO ON THE DISPOSAL
OF THIS PROD/ARRANGE FOR DISPOSAL BY A LICENSED DISPOSAL COMPANY.
DISPOSE OF IN ACCORDANCE WITH FEDERAL, STATE AND LOCAL REGULATIONS
.

Toxicological Information:RTECS NUMBER: VJ7000000. TOX DATA &
REFERENCES: ORL; HMN; TDLO: 180 MG/KG CONJUNCTIVE IRRIT; DERM 1977.
BRITISH MEDICAL JOURNAL. 2, 1189. ORL; MAN; TDLO: 13 MG/KG/2D TOX
EFTS ON SENSE ORGANS 1976. BRI TISH MEDICAL JOURNAL. 1, 199. ORL;
WMN; TDLO: 504 MG/KG MUSC WEAK; DYSPNEA; APLASTIC ANEMIA 1989.
AMERICAN JOURNAL OF MEDICINE. 87, 459. ORL; WMN; TLDO: 315
MG/KG/5W-I DERM 1987. JOURNAL OF THE AMERIC AN ACADEMY OF
DERMATOLOGY. 17, 303. ORL; MAN; LDLO: 857 MG/KG NAUS; VOMIT; DERM
1978. JAMA, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 240, 2283.
ORL; RAT; LD50: 1570 MG/KG 1970. JAPANESE JOURNAL OF ANTIBIOTICS.
23, 242. (OTHER INFO)

Disclaimer (provided with this information by the compiling agencies):
This information is formulated for use by elements of the Department
of Defense. The United States of America in no manner whatsoever,
expressly or implied, warrants this information to be accurate and
disclaims all liability for its use. Any person utilizing this
document should seek competent professional advice to verify and
assume responsibility for the suitability of this information to their
particular situation.

Ecological:NO INFORMATION AVAILABLE. OTHER INFO: CHEMOTHERAPIA (BASEL,
1954-70). 16, 316. REPRO EFTS & REFERENCES: ORL; RAT; DOSE: 1400
MG/KG CRANIOFACIAL & MUSCULOSKELETAL SYS DEVELOPMENTAL ABNORMS
1969. COMPT ES RENDUS DES SEANCES DE L'ACADEMIE DES SCIENCES, SERIE
D: SCIENCES NATURELLES. 269, 2147. ORL; RAT; DOSE: 3200 MG/KG TOX
EFTS ON LITTER SIZE 1969. COMPTES RENDUS DES SEANCES DE L'ACADEMIE
DES SCIENCE S, SERIE D: SCIENCES NATURELLES. 269, 2147. ORL; RAT;
DOSE: 4 G/KG OTHER DEVELOPMENTAL ABNORMS 1970. ANTIBIOTICA ET
CHEMOTHERAPIA (BASEL, 1954-70). 16, 316. ORL; RAT; DOSE: 800 MG/KG
POST-IMPLANTATION MORTALITY; UROGENITAL (TRANSPORT INFO)

Transport Information:UN NUMBER: N/A. PROPER SHIPPING NAME: N/A. IATA
CLASS: N/A. IATA PACKING GROUP: N/A. ECOLOGICAL INFO: & CNS
DEVELOPMENTAL ABNORMS 1991. PROBLEMY TUBERKULEZA. PROBLEMS OF
TUBERCULOSIS. 69(2), 67. ORL; MUS; DOSE: 2200 MG/KG CRANIOFACIAL &
MUSCULOSKELETAL SYS DEVELOPMENTAL ABNORMS 1969. COMPTES RENDUS DES
SEANCES DE L'ACADEMIE DES SCIENCES, SERIE D: SCIENCES NATURELLES.
269, 2147. ORL; RBT; DOSE: 260 0 MG/KG POST-IMPLANTATION MORTALITY
1970. ANTIBIOTICA ET CHEMOTHERAPIA (BASEL, 1954-70). 16, 316.
GENETIC DATA & REFERENCES: HLA; HMN; DOSE: 250 MG/L DNA INHIBITION
1984. INDIAN JOURNAL OF EXPERIMENTA L BIOLOGY. (SARA REG INFO)

SARA Title III Information:N/P. TRANSPORT INFO: 22, 350. LYM; HMN;
DOSE: 100 MG/L DNA INHIBITION 1974. BIOCHEMICAL & BIOPHYSICAL
RESEARCH COMMUNICATIONS. 60, 96. LYM; HMN; DOSE: 25 MG/L
CYTOGENETIC ANALYSIS 1977. MUTATION RESEA RCH. 48, 215. OTH; HMN;
DOSE: 78 MG/L CYTOGENETIC ANLAYSIS 1974. EXPERIENTIA. 30, 484. AST;
MUS; DOSE: 5 MG/KG HOST-MEDIATED ASSAY 1984. MUTATION RESEARCH.
141, 171. HLA; HMN; DOSE: 150 MG/L OTHER MUT ATION TEST SYS 1974.
EXPERIENTIA. 30, 484. HLA; HMN; DOSE: 250 MG/L OTHER MUTATION TEST
SYS 1984. INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY. 22, 350. OTH;
HMN; DOSE: 150 MG/L OTHER MUTATION TEST SYS 1974 . EXPERIENTIA. 30,
484. (STATE REG INFO)
Federal Regulatory Information:REGULATORY INFO: XN, XI. RISK PHRASES -
R20/21/22: HARMFUL BY INHALATION, IN CONTACT WITH SKIN AND IF
SWALLOWED. R36/37/38: IRRITATING TO EYES, RESPIRATORY SYSTEM AND
SKIN. R40: POSSIBLE RISK OF IRREV ERSIBLE EFFECTS. SAFETY PHRASES -
S22: DO NOT BREATHE DUST. S24/25: AVOID CONTACT WITH SKIN AND EYES.
S26: IN CASE OF CONTACT WITH EYES, RINSE IMMEDIATELY WITH PLENTY OF
WATER AND SEEK MEDICAL ADVICE. S36/37/39: WEAR SUITABLE PROTECTIVE
CLOTHING, GLOVES AND EYE/FACE PROTECTION. S45: IN CASE OF ACCID ENT
OR IF YOU FEEL UNWELL, SEEK MEDICAL ADVICE IMMEDIATELY.
State Regulatory Information:N/P. SARA REG INFO: TURORIGENIC DATA &
REFERENCES: ORL; MUS; DOSE: 8400 MG/KG/60W-C NEOPLASTIC BY RTECS
CRITERIA; LIVER TUMORS 1978. TOX & APPLIED PHARMACOLOGY. 43, 293.
REVIEWS: IARC CANCER REVIEW: A NIMAL LIMITED EVID REFERENCE 1980.
IARC MONO. 24, 243. IARC CANCER REVIEW: GRP 3 REFERENCE 1987. IARC
MONO, SUPP. 7, 56. IARC CANCER REVIEW: HUMAN NO ADEQ DATA REFERENCE
1980. IARC MONO. 24, 243. TOX REVIEW REFERENCE 1973. MUENCHENER
MEDICINISCHE WOCHENSCHRIFT 115, 1685. TOX REVIEW REFERENCE 1980. L
ANCET. 2, 1285. REFER TO RTECS FOR DEFINITION OF ABBREVIATIONS
USED & FOR ADDNL INFO. THIS REPORT CNTNS ONLY SELECTED INFO FROM
RTECS.